DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · IEX Real-Time Price · USD
+0.045 (1.91%)
Jun 14, 2024, 11:59 AM EDT - Market open

Company Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke.

Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases.

In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016.

DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics Inc.
DiaMedica Therapeutics logo
Country United States
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 18
CEO Dietrich John Pauls MBA

Contact Details

301 Carlson Parkway, Suite 210
Minneapolis, Minnesota 55305
United States
Phone (763) 496-5454
Website diamedica.com

Stock Details

Ticker Symbol DMAC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001401040
CUSIP Number 25253X207
ISIN Number CA25253X2077
SIC Code 2834

Key Executives

Name Position
Dietrich John Pauls MBA President, Chief Executive Officer and Director
Scott Kellen C.P.A. Chief Financial Officer and Corporate Secretary
Dr. Kirsten L. Gruis M.D., M.S. Independent Consultant
Julie VanOrsdel Daves CCRP Senior Vice President of Clinical Development Operations
Dr. Ambarish Shah Ph.D. Chief Technology Officer
Dominic R. Cundari Chief Commercial Officer
David J. Wambeke Chief Business Officer
Dr. Lorianne K. Masuoka M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
May 24, 2024 S-8 Securities to be offered to employees in employee benefit plans
May 23, 2024 8-K Current Report
May 8, 2024 10-Q Quarterly Report
May 8, 2024 8-K Current Report
Apr 10, 2024 8-K Current Report
Apr 9, 2024 EFFECT Notice of Effectiveness
Apr 4, 2024 ARS Filing
Apr 4, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 4, 2024 DEF 14A Other definitive proxy statements
Mar 26, 2024 UPLOAD Filing